Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$27,000.00

Investing the pro-tumorigenic role of RNA pseudouridylation in ovarian cancer

FY 2024-25

Summary
Ovarian cancer is the deadliest gynecologic cancer, claiming the lives of about 1,900 women each year in Canada. Most ovarian cancers are diagnosed at late stages, when there are unfortunately no effective treatments for this stage. In order to develop novel therapeutic strategies, we need to better understand the molecular basis of ovarian cancer. At the molecular level, cancer cells have a completely different programming than normal cells, which is what makes them grow and proliferate excessively. RNAs are the molecules that help carry out genetic instructions, and they can be chemically modified, affecting their stability and activity. These RNA modifications are also altered in cancer cells. We have identified a protein that modifies RNA molecules as a potential key player in ovarian cancer progression. This protein is found at much higher levels in ovarian cancer tissues than in non-cancerous tissues, and patients with more of it tend to have worse survival outcomes. In this study, I will investigate how this protein drives the progression of ovarian cancer. Our early experiments show that reducing this protein in ovarian cancer cells slows their growth and reduces their ability to form new colonies, supporting its critical role in the cancer development. Now, I will explore two major questions. First, I will study how reducing the amount of this protein impacts cancer cell behavior, including their ability to grow, survive, form tumors, and spread. Second, I will identify which RNA molecules are regulated by this protein and how its activity alters their stability and expression/activity. If our study identifies this protein is essential for ovarian cancer, targeting this protein might provide a novel and more effective way to treat this challenging disease.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529760
Name
Nakevska Zorica
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investing the pro-tumorigenic role of RNA pseudouridylation in ovarian cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Epitranscriptomics; Gynecological Cancers; Nhp2 (Nonhistone Protein 2); Ovarian Cancer; Pseudouridine; Rna Pseudouridylation; Rna-Sequencing
Abstract
Ovarian cancer is the deadliest gynecologic cancer, claiming the lives of about 1,900 women each year in Canada. Most ovarian cancers are diagnosed at late stages, when there are unfortunately no effective treatments for this stage. In order to develop novel therapeutic strategies, we need to better understand the molecular basis of ovarian cancer. At the molecular level, cancer cells have a completely different programming than normal cells, which is what makes them grow and proliferate excessively. RNAs are the molecules that help carry out genetic instructions, and they can be chemically modified, affecting their stability and activity. These RNA modifications are also altered in cancer cells. We have identified a protein that modifies RNA molecules as a potential key player in ovarian cancer progression. This protein is found at much higher levels in ovarian cancer tissues than in non-cancerous tissues, and patients with more of it tend to have worse survival outcomes. In this study, I will investigate how this protein drives the progression of ovarian cancer. Our early experiments show that reducing this protein in ovarian cancer cells slows their growth and reduces their ability to form new colonies, supporting its critical role in the cancer development. Now, I will explore two major questions. First, I will study how reducing the amount of this protein impacts cancer cell behavior, including their ability to grow, survive, form tumors, and spread. Second, I will identify which RNA molecules are regulated by this protein and how its activity alters their stability and expression/activity. If our study identifies this protein is essential for ovarian cancer, targeting this protein might provide a novel and more effective way to treat this challenging disease.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nakevska, Zorica
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~